The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Looking for a Therapeutic Edge Among CDK Inhibitors
March 13th 2018Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.
MDAdvantage Announces 2018 Recipients of Prestigious Excellence in Medicine Awards
March 9th 2018MDAdvantage Insurance Company, a leading provider of medical professional liability insurance, today announced the 2018 EJI Excellence in Medicine award recipients. Honoring New Jersey healthcare providers, the Excellence in Medicine Awards are among the highest honors presented to New Jersey's medical community.
April Camiling Honored with Excellence in Nursing Award from Modern Healthcare
March 9th 2018Hackensack Meridian Health Hackensack University Medical Center is proud to announce that April Camiling, MSN, RN, AOCNS, BMTCN, oncology nurse specialist in Blood and Marrow Transplant (BMT) at John Theurer Cancer Center - Hackensack University Medical Center, has been recognized by Modern Healthcare as a Rising Star recipient in the 2018 Excellence in Nursing Award program.
Hematopathologist Highlights Latest Developments in the Field
March 8th 2018Nichon L. Grupka, MD, discusses advances in hematopathology, specifically mutations as prognostic indicators, disease-associated versus disease-causing mutations, and advice for physicians who are working to navigate the field.
Surgery, Brachytherapy-based Radiotherapy Induce Similar Survival in Localized Prostate Cancer
March 7th 2018Investigators found no statistically significant difference in survival between radical prostatectomy alone and external beam radiotherapy plus brachytherapy with or without ADT after adjusting for imbalances in prostate cancer prognostic factors.